<DOC>
	<DOC>NCT00668863</DOC>
	<brief_summary>To evaluate the efficacy, safety and pharmacokinetics of sunitinib plus FOLFIRI (irinotecan, 5-FU and l-leucovorin) in the first-line treatment of Japanese mCRC patients</brief_summary>
	<brief_title>Study Of Sunitinib With FOLFIRI In Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Patient with histologically or cytologicallyconfirmed colorectal adenocarcinoma with unresectable or metastatic disease documented on diagnostic imaging studies. Patient must have at least one RECISTdefined measurable lesion that has not been treated with prior local therapy. History of another primary malignancy within 3 years prior to study entry, with the exception of nonmelanoma skin cancer and in situ carcinoma of the uterine cervix. Current, recent, or planned participation in an experimental treatment drug study other than this protocol.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>